- Home
- TRMD vs HCM Comparison
TRMD vs HCM Comparison
Compare TRMD & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | HCM |
|---|---|---|
| Founded | 1889 | 2000 |
| Country | United Kingdom | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TRMD | HCM |
|---|---|---|
| Price | $29.30 | $15.18 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 1 | 1 |
| Target Price | ★ $34.00 | $13.75 |
| AVG Volume (30 Days) | ★ 854.6K | 31.0K |
| Earning Date | 05-13-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | $9.61 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.93 | $13.06 |
| 52 Week High | $31.76 | $19.50 |
Technical Indicators
Market Signals| Indicator | TRMD | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 59.27 | 59.60 |
| Support Level | $21.54 | $14.69 |
| Resistance Level | $31.76 | $15.49 |
| Average True Range (ATR) | 0.96 | 0.46 |
| MACD | 0.21 | 0.11 |
| Stochastic Oscillator | 75.80 | 73.74 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.